



Summary of Studies Supporting USDA Product Licensure

| | |
|---|---|
| Establishment Name | Zoetis Inc. |
| USDA Vet Biologics Establishment Number | 190 |
| Product Code | 1905.24 |
| True Name | Rabies Vaccine, Killed Virus |
| Tradename(s) / Distributor or Subsidiary (if different from manufacturer) | Defensor - Zoetis Industria de Produtos Defensor 1 - No distributor specified Defensor 1 - Zoetis Argentina Defensor 1 - Zoetis Colombia S.A.S. Defensor 1 - Zoetis Mexico Defensor 3 - No distributor specified Defensor 3 - SARI, Belophram Defensor 3 - Zoetis (Thailand) Limited Defensor 3 - Zoetis Ecuador Cia Ltda. Defensor 3 - Zoetis Hayvan Sagligi Ltd Defensor 3 - Zoetis Korea Defensor 3 - Zoetis Panama Defensor 3 - Zoetis Russia Defensor 3 - Zoetis Schweiz GmbH, Delemont Defensor 3 - Zoetis South Africa Ltd Defensor 3 - Zoetis import Egypt Nobivac 3 - Rabies - Intervet, Inc. Nobivac 3 Rabies - Intervet, Inc. |
| Date of Compilation Summary | February 25, 2021 |

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

| Study Type | Efficacy | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|-----------|----------------|-----|------------------------------------|--|------------------------------------|-----|--|----|--|----------------|---|----------------|---|----------|----|-----|---|---|----|------------|---|---|----|-----|----|
| Pertaining to | Rabies Virus (RV) | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Study Purpose | To demonstrate effectiveness and 1 year duration of immunity against rabies disease | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Product Administration | 1 dose subcutaneously (SC) | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Study Animals | Forty three ferrets 12 weeks of age, divided into 27 vaccinates and 16 controls | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Challenge Description | Forty three animals (27 vaccinates; 16 controls) were challenged 373 days post-vaccination | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Interval observed after challenge | All challenged animals were observed twice daily up to 90 days or until humane endpoints of clinical signs due to RV were observed | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Results | <p>An animal was classified as affected if it had one or more clinical signs of rabies disease post challenge and/or was positive by direct fluorescent antibody (dFA) in the brain stem tissue.</p> <p><u>Table 1. Number of Animals with Rabies Disease</u></p> <table border="1"> <thead> <tr> <th rowspan="3">Treatment</th> <th colspan="4">Disease</th> <th rowspan="3">Total Animals Challenged Per Group</th> </tr> <tr> <th colspan="2">YES</th> <th colspan="2">NO</th> </tr> <tr> <th>No. of Animals</th> <th>%</th> <th>No. of Animals</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Controls</td> <td>16</td> <td>100</td> <td>0</td> <td>0</td> <td>16</td> </tr> <tr> <td>Vaccinates</td> <td>0</td> <td>0</td> <td>27</td> <td>100</td> <td>27</td> </tr> </tbody> </table> <p>The requirements of 9 CFR 113.209 were met.</p> <p>The raw data for the control group is shown on the attached pages. There were no clinical signs of rabies disease or positive dFA test results for the vaccinate group.</p> | Treatment | Disease | | | | Total Animals Challenged Per Group | YES | | NO | | No. of Animals | % | No. of Animals | % | Controls | 16 | 100 | 0 | 0 | 16 | Vaccinates | 0 | 0 | 27 | 100 | 27 |
| Treatment | Disease | | | | Total Animals Challenged Per Group | | | | | | | | | | | | | | | | | | | | | | |
| | YES | | NO | | | | | | | | | | | | | | | | | | | | | | | | |
| | No. of Animals | % | No. of Animals | % | | | | | | | | | | | | | | | | | | | | | | | |
| Controls | 16 | 100 | 0 | 0 | 16 | | | | | | | | | | | | | | | | | | | | | | |
| Vaccinates | 0 | 0 | 27 | 100 | 27 | | | | | | | | | | | | | | | | | | | | | | |
| USDA Approval Date | 01 December 2015 | | | | | | | | | | | | | | | | | | | | | | | | | | |

Table 2: Individual Animal Daily Clinical Signs for Controls

| Animal ID | Days post-challenge | | | | | | | | | |
|-----------|---------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | 0 DPC | 1 DPC | 2 DPC | 3 DPC | 4 DPC | 5 DPC | 6 DPC | 7 DPC | 8 DPC | 9 DPC |
| 9052 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9054 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9061 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9062 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9063 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9065 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9066 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9069 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9071 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9080 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9082 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9083 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9096 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9098 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9103 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

| Animal ID | Days post-challenge | | | | | dFA* positive Y/N |
|-----------|---------------------|------------------------|--------|----------------------------|--------------------|-------------------|
| | 10 DPC | 11 DPC | 12 DPC | 13 DPC | 14 DPC | Y |
| 9052 | 0 | 0 | NR, HY | PA, NR, DI, OT, ED, HY | - | Y |
| 9054 | 0 | 0 | NR | PA, NR, HY, DI, ED | - | Y |
| 9061 | 0 | SA, PA, NR, DE, ED | - | - | - | Y |
| 9062 | 0 | SA, PA, NR, HY, OT, ED | - | - | - | Y |
| 9063 | 0 | SA, PA, NR, HY, ED | - | - | - | Y |
| 9065 | 0 | 0 | DE | SA, PA, OT, NR, HY, DI, ED | - | Y |
| 9066 | 0 | 0 | - | - | SA, NR, HY, DI, ED | Y |
| 9069 | 0 | PA, DE, OT, ED | - | - | - | Y |
| 9071 | 0 | PA, NR, ED | - | - | - | Y |
| 9080 | 0 | SA, OT, HY, ED | - | - | - | Y |
| 9082 | 0 | 0 | 0 | PA, NR, HY, DI, DE, ED | - | Y |
| 9083 | 0 | PA, NR, HY, DE, ED | - | - | - | Y |
| 9096 | 0 | PA, OT, NR, HY, ED | - | - | - | Y |
| 9098 | 0 | PA, NR, DI, ED | - | - | - | Y |
| 9103 | 0 | SA, OT, NR, HY, ED | - | - | - | Y |
| 9104 | 0 | SA, PA, NR, HY, ED | - | - | - | Y |

Clinical signs

| | | | |
|----|------------------------|----|--------------------|
| 0 | Normal | SA | Salivation |
| DE | Depression | LB | Labored Breathing |
| NR | Nervousness / Restless | OT | Other |
| PA | Paresis | ED | Euthanasia / Death |
| HY | Hyperresponse | | |
| DI | Disorientation | | |

*direct fluorescent antibody

| | |
|--|---|
| Study Type | Efficacy |
| Pertaining to | Rabies Virus |
| Study Purpose | To demonstrate effectiveness and 1 year duration of immunity and 3 year duration of immunity against rabies disease. |
| Product Administration | Dog: Subcutaneous (SC) Dog: Intramuscular (IM) |
| Study Animals | Dogs |
| Challenge Description | |
| Interval observed after challenge | |
| Results | Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date. |
| USDA Approval Date | 15 October 1992 |

| | |
|--|---|
| Study Type | Efficacy |
| Pertaining to | Rabies Virus |
| Study Purpose | To demonstrate effectiveness and 1 year duration of immunity and 3 year duration of immunity against rabies disease. |
| Product Administration | Cat: Subcutaneous (SC) |
| Study Animals | Cats |
| Challenge Description | |
| Interval observed after challenge | |
| Results | Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date. |
| USDA Approval Date | 15 October 1992 |

| | |
|--|---|
| Study Type | Efficacy |
| Pertaining to | Rabies Virus |
| Study Purpose | To demonstrate effectiveness and 1 year duration of immunity against rabies disease. |
| Product Administration | |
| Study Animals | Cattle and Sheep |
| Challenge Description | |
| Interval observed after challenge | |
| Results | Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date. |
| USDA Approval Date | 15 October 1992 |

| Study Type | Safety | | | | | | | | | | | | | | | | | | | | |
|--|--|----------------------|-----------------------|----------------------|-----------------------|---|-------------------|------------------|---------------------|-------------|-------------|----------------------|-----------------------|----------------------------------|--------------|-----------|--------------|-----------------------|--------------|-----------|--------------|
| Pertaining to | ALL | | | | | | | | | | | | | | | | | | | | |
| Study Purpose | Demonstrate safety under typical field conditions | | | | | | | | | | | | | | | | | | | | |
| Product Administration | One dose administered subcutaneously (SC) | | | | | | | | | | | | | | | | | | | | |
| Study Animals | Two hundred ferrets (50 between 12 and 13 weeks of age, 150 \geq 13 weeks) tested in 3 distinct geographic locations | | | | | | | | | | | | | | | | | | | | |
| Challenge Description | N/A | | | | | | | | | | | | | | | | | | | | |
| Interval observed after challenge | N/A | | | | | | | | | | | | | | | | | | | | |
| Results | <p>Animals were observed for 20 minutes immediately post-vaccination (immediate post-vaccination) and for 10 days post-vaccination (late post-vaccination).</p> <p><u>Table 1: Immediate Post-Vaccination Reactions</u></p> <table border="1"> <thead> <tr> <th>Observation</th> <th>Study Total</th> <th>Minimum Age 12 weeks</th> <th>Older \geq13 weeks</th> </tr> </thead> <tbody> <tr> <td>Injection Site Self-trauma (scratching)</td> <td><u>2/200 (1%)</u></td> <td><u>0/50 (0%)</u></td> <td><u>2/150 (1.3%)</u></td> </tr> </tbody> </table> <p><u>Table 2: Late Post-Vaccination Reactions^a</u></p> <table border="1"> <thead> <tr> <th>Observation</th> <th>Study Total</th> <th>Minimum Age 12 weeks</th> <th>Older \geq13 weeks</th> </tr> </thead> <tbody> <tr> <td>Depression/Lethargy^b</td> <td>1/200 (0.5%)</td> <td>0/50 (0%)</td> <td>1/150 (0.7%)</td> </tr> <tr> <td>Vomiting^b</td> <td>1/200 (0.5%)</td> <td>0/50 (0%)</td> <td>1/150 (0.7%)</td> </tr> </tbody> </table> <p>^a Late Post-Vaccination observations reported by owner only if they occurred (by exception) ^b Both reactions were related to the same animal</p> <p>No other post-vaccination reactions were noted.</p> | Observation | Study Total | Minimum Age 12 weeks | Older \geq 13 weeks | Injection Site Self-trauma (scratching) | <u>2/200 (1%)</u> | <u>0/50 (0%)</u> | <u>2/150 (1.3%)</u> | Observation | Study Total | Minimum Age 12 weeks | Older \geq 13 weeks | Depression/Lethargy ^b | 1/200 (0.5%) | 0/50 (0%) | 1/150 (0.7%) | Vomiting ^b | 1/200 (0.5%) | 0/50 (0%) | 1/150 (0.7%) |
| Observation | Study Total | Minimum Age 12 weeks | Older \geq 13 weeks | | | | | | | | | | | | | | | | | | |
| Injection Site Self-trauma (scratching) | <u>2/200 (1%)</u> | <u>0/50 (0%)</u> | <u>2/150 (1.3%)</u> | | | | | | | | | | | | | | | | | | |
| Observation | Study Total | Minimum Age 12 weeks | Older \geq 13 weeks | | | | | | | | | | | | | | | | | | |
| Depression/Lethargy ^b | 1/200 (0.5%) | 0/50 (0%) | 1/150 (0.7%) | | | | | | | | | | | | | | | | | | |
| Vomiting ^b | 1/200 (0.5%) | 0/50 (0%) | 1/150 (0.7%) | | | | | | | | | | | | | | | | | | |
| USDA Approval Date | 6 July 2016 | | | | | | | | | | | | | | | | | | | | |

| | |
|--|---|
| Study Type | Safety |
| Pertaining to | Rabies Virus |
| Study Purpose | Demonstrate safety under typical field conditions |
| Product Administration | |
| Study Animals | Cattle and Sheep |
| Challenge Description | |
| Interval observed after challenge | |
| Results | Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date. |
| USDA Approval Date | 15 October 1992 |

| | |
|--|---|
| Study Type | Safety |
| Pertaining to | Rabies Virus |
| Study Purpose | Demonstrate safety under typical field conditions |
| Product Administration | |
| Study Animals | Dogs and Cats |
| Challenge Description | |
| Interval observed after challenge | |
| Results | Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date. |
| USDA Approval Date | 07 August 1991 |